IG Studies Impact Of Part D Plans Favoring Brand Hep C Drugs

By John Wilkerson / April 19, 2021 at 4:22 PM
Years after Gilead launched authorized generics of its hepatitis C drugs, Part D plans aren’t using them, even though the generics and far cheaper and identical, so the HHS Inspector General is looking into the impact that Part D plans’ preference for expensive hepatitis C drugs has on beneficiaries, according to the IG’s most recent work agenda. In 2019, Medicare Part D spent about $2.5 billion on hepatitis C drugs to treat 50,000 beneficiaries. Three drugs -- Harvoni, Epclusa, and...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.